Lack of Knowledge on Clinical Advances Achieved by New Generation of Biomarker Tests for Prostate Cancer

Independent Survey Results Presented at the 5th Global Congress on Prostate Cancer (PROSCA) Indicate Untapped Market Potential for SelectMDx.

MDxHealth SA (Euronext: MDXH.BR) today announced that results from an independent urology survey identify lack of knowledge on the new generation biomarker tests for Prostate Cancer. Survey data were presented on June 28th at the fifth Global Congress on Prostate Cancer in Lisbon, Portugal.  


In his keynote presentation "Biomarkers in 2017," Prof. Nicolaas Lumen, MD, PhD, Head of Clinic Urology at University Hospital Gent, Belgium, reported that almost half of urologists do not recommend any diagnostic biomarker tests to patients. Survey data identified that the limited utilization figures result from a lack of familiarity with the clinical advances offered by new generation tests. Of the 300 urologists participating in Dr. Lumen's survey, biomarker test utilization would nearly double (to 90%) if the urologists had access to a test with a negative predictive value (NPV) of 98% for clinically significant cancer.


"The results of this survey highlighted that urologists are more familiar with older biomarker tests like PCA3 that do not have such a high NPV for significant prostate cancer," said Prof. Dr. Lumen. "The new generation biomarker tests are more accurate to identify clinically significant prostate cancer and are valuable tools for further risk assessment to determine whether or not to proceed with biopsy."


"Dr. Lumen's survey clearly identifies a significant untapped market for our SelectMDx for Prostate Cancer test." said Dr. Jan Groen, CEO of MDxHealth, "SelectMDx is an affordable non-invasive liquid biomarker test with a 98% NPV for Gleason score 7 or greater prostate cancer and is available for use in Europe and the US."


A recording of Dr. Lumen's survey data presentation and his full lecture will be available on


About SelectMDx for Prostate Cancer

Of the more than 2 million prostate biopsies performed each year in the US and Europe, less than a third find cancer. Most of these men could have avoided a painful and invasive prostate biopsy procedure, with its associated complications and costs. SelectMDx for Prostate Cancer is a proprietary urine-based, molecular diagnostic test that offers a non-invasive 'liquid biopsy' method to assess a man's risk for prostate cancer. SelectMDx helps identify men at increased risk of harboring aggressive, potentially lethal, prostate cancer who may benefit most from a prostate biopsy and earlier detection. The test delivers a negative predictive value (NPV) of 98% for clinically significant disease, helping to reduce diagnostic procedures, such as MRI and invasive prostate biopsies, by approximately 50%, thereby reducing healthcare costs.


About MDxHealth

MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company's European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit and follow us on social media at:, and



Interested in a regular update of the Life Sciences and biotech sector in Flanders?